JoAnn V. Pinkerton, MD

In the 52-week OASIS-3 trial, elinzanetant significantly reduced the frequency and severity of hot flashes and night sweats.

Postmenopausal osteoporosis is a major health problem, primarily because of the severe morbidity and mortality associated with osteoporotic fractures.